- Trials with a EudraCT protocol (34)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
34 result(s) found for: Cross reactivity.
Displaying page 1 of 2.
EudraCT Number: 2009-017828-54 | Sponsor Protocol Number: 1131/09 | Start Date*: 2011-03-28 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Cross-reactivity and tolerability of ertapenem in patients with IgE-mediated allergy to -lactams. | |||||||||||||
Medical condition: allergy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000576-13 | Sponsor Protocol Number: INO102141 | Start Date*: 2004-11-03 |
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||
Full Title: A two-centre, randomised, double-blind, double-dummy, placebo-controlled, 3-period cross-over study to evaluate the effect of treatment with repeat doses of GW274150 on the allergen-induced late as... | ||
Medical condition: Mild asthma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-005209-30 | Sponsor Protocol Number: AGO/2013/013 | Start Date*: 2014-01-07 | ||||||||||||||||
Sponsor Name:Ghent University Hospital | ||||||||||||||||||
Full Title: The effect of Hydroxyethylstarch 6% 130/0.4 in a balanced electrolyte solution (Volulyte®) compared to gelatine (Geloplasma®) on microvascular reactivity and tissue oxygen saturation during haemodi... | ||||||||||||||||||
Medical condition: Patients undergoing elective coronary artery bypass grafting surgery. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005502-25 | Sponsor Protocol Number: ZP1848-20110 | Start Date*: 2021-04-11 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: A 104-Week, Multicenter, Single-Arm, Long-Term, Phase 3 Extension Trial Investigating the Safety and Efficacy of Glepaglutide in Adult Patients with Short Bowel Syndrome (SBS) Completing the EASE S... | |||||||||||||
Medical condition: Short bowel syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001944-36 | Sponsor Protocol Number: 20170149 | Start Date*: 2018-05-21 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000763-33 | Sponsor Protocol Number: 20160283 | Start Date*: 2017-12-01 |
Sponsor Name:Amgen, Inc. | ||
Full Title: A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Efavaleukin Alfa in Adult Subjects with Steroid Refractory Chronic Graft versu... | ||
Medical condition: Steroid Refractory Chronic Graft versus Host Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-001027-59 | Sponsor Protocol Number: NEO-040 | Start Date*: 2008-10-21 |
Sponsor Name:University of Dundee | ||
Full Title: A Randomised, Double-Blind, Double-Dummy Cross-Over Study to demonstrate Superiority of Fluticasone/ Salmeterol pMDI over double the dose of Fluticasone pMDI on Methacholine Hyper-Reactivity in Pat... | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005469-12 | Sponsor Protocol Number: NEO-012 | Start Date*: 2006-01-06 |
Sponsor Name:Neolab Limited | ||
Full Title: A Phase III, randomised, double-blind, double-dummy cross-over study to compare two dry powder inhaled formulations of budesonide on methacholine hyper-reactivity in patients with stable, persisten... | ||
Medical condition: Stable, persistent, moderate asthma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003566-13 | Sponsor Protocol Number: AF219-009 | Start Date*: 2013-11-06 | |||||||||||
Sponsor Name:Afferent Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Way Cross-over Study to evaluate the effect of AF-219 on methacholine hyper-reactivity in subjects with asthma. | |||||||||||||
Medical condition: Stable Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005194-27 | Sponsor Protocol Number: ZP1848-20060 | Start Date*: 2021-06-30 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: A Single-Center Phase 3b Trial Investigating the Long-term Effect on Intestinal Absorption, Nutritional Status and Long-Term Safety of treatment with Glepaglutide in Patients with Short Bowel Syndr... | |||||||||||||
Medical condition: Short bowel syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005339-83 | Sponsor Protocol Number: IPA101985 | Start Date*: 2006-05-19 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A two-centre, randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with repeat doses of inhaled GSK256066 on the allergen-induced late asthmat... | |||||||||||||
Medical condition: Allergen-induced late asthmatic response | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003012-23 | Sponsor Protocol Number: AQX-1125-200 | Start Date*: 2011-10-10 |
Sponsor Name:AQUINOX PHARMACEUTICALS INC | ||
Full Title: A phase IIa single-centre, randomised, double-blind, placebo-controlled, two-way cross-over allergen challenge study to evaluate the effect of treatment with once daily AQX-1125 on the late asthmat... | ||
Medical condition: Mild to moderate asthma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004345-14 | Sponsor Protocol Number: FB/PS/14/169/07 | Start Date*: 2007-12-05 | |||||||||||
Sponsor Name:Chiesi Farmaceutici SpA | |||||||||||||
Full Title: Dose response evaluation of CHF 1535 HFA pMDI in asthmatic patients using lung function, adenosine monophosphate bronchial challenge and fractional exhaled nitric oxide (FENO). Randomized, double... | |||||||||||||
Medical condition: Mild Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007197-31 | Sponsor Protocol Number: 3001088 | Start Date*: 2008-04-22 | |||||||||||
Sponsor Name:Orion Corporation Orion Pharma | |||||||||||||
Full Title: EFFECTS OF ORAL LEVOSIMENDAN ON AMBULATORY ELECTROCARDIOGRAPHIC VARIABLES AND CEREBROVASCULAR REACTIVITY IN PATIENTS WITH RECENT STROKE OR TIA. A RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED, DOSE ... | |||||||||||||
Medical condition: Stroke or TIA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Prematurely Ended) HU (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002177-37 | Sponsor Protocol Number: 1321.7 | Start Date*: 2016-06-01 | ||||||||||||||||
Sponsor Name:Boehringer Ingelheim AB | ||||||||||||||||||
Full Title: Single dose, open label, uncontrolled, safety trial of intravenous administration of idarucizumab to paediatric patients enrolled from ongoing phase IIb/III clinical trials with dabigatran etexilat... | ||||||||||||||||||
Medical condition: | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) LT (Completed) CZ (Completed) IT (Completed) DE (Completed) Outside EU/EEA GR (Completed) HU (Completed) BE (Completed) ES (Prematurely Ended) BG (Completed) AT (Completed) FI (Completed) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-003188-31 | Sponsor Protocol Number: INF-V-A007 | Start Date*: 2011-10-24 | |||||||||||
Sponsor Name:CRUCELL SWITZERLAND AG | |||||||||||||
Full Title: A Phase IV, open label study to evaluate the immune response against homogenous and heterogenous circulating strains in elderly subjects after vaccination with Inflexal V | |||||||||||||
Medical condition: Healthy female and male elderly subjects where influenza vaccination is suggested | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000712-30 | Sponsor Protocol Number: ABR-71432 | Start Date*: 2021-06-07 | |||||||||||
Sponsor Name:Radboudumc | |||||||||||||
Full Title: Targeted glucocorticoid administration to improve safety learning in PTSD patients with HPA axis dysregulation | |||||||||||||
Medical condition: Posttraumatic Stress Disorder (PTSD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000374-37 | Sponsor Protocol Number: 161505 | Start Date*: 2016-10-28 | |||||||||||
Sponsor Name:Baxalta Innovations GmbH | |||||||||||||
Full Title: Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculone... | |||||||||||||
Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DK (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) NO (Completed) GR (Completed) SK (Prematurely Ended) DE (Completed) PL (Completed) HR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004798-34 | Sponsor Protocol Number: ATB200-02 | Start Date*: 2016-08-01 | |||||||||||
Sponsor Name:Amicus Therapeutics, Inc. | |||||||||||||
Full Title: AN OPEN-LABEL, FIXED-SEQUENCE, ASCENDING-DOSE, FIRST-IN-HUMAN STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF INTRAVENOUS INFUSIONS OF ATB200 CO-ADMINI... | |||||||||||||
Medical condition: Pompe Disease - acid maltase deficiency or glycogen storage disease type II. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006249-42 | Sponsor Protocol Number: D5252C00008 | Start Date*: 2008-02-28 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 3, randomised, open-label, cross-over study to compare HFA vs CFC pMDI formulations of budesonide on methacholine hyper-reactivity in patients with stable, persistent, mild to moderate asthma | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
